Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza ...

Novo Nordisk A/S (NYSE: NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ...

After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo Nordisk’s aging GLP-1 mainstay. Novo Nordisk and ...

Generic Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with Type 2 diabetes mellitus. Lupin is releasing ...

This article first appeared on GuruFocus. A class action lawsuit filed on Friday is bringing Novo Nordisk (NYSE:NVO) back into the spotlight, with allegations that its handling of competition around ...

June 24 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab said on Monday it had launched a generic version of Novo Nordisk's (NOVOb.CO), opens new tab Victoza to treat patients with type 2 ...

Credit: Teva. The generic product is supplied in a prefilled, single-patient-use pen. The generic product is supplied in a prefilled, single-patient-use pen. Teva has launched an authorized generic ...